Characterization and evaluation of nanostructured lipid carrier as a vehicle for oral delivery of etoposide

European Journal of Pharmaceutical Sciences

Volumn 43, Issue 3, 2011, Pages 174-179

  Zhang, Tiecheng ^a,b   Chen, Jianian ^a   Zhang, Yi ^a   Shen, Qi ^a   Pan, Weisan ^b  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Etoposide; Nanostructured lipid carriers; Oral delivery; Pharmacokinetics

Indexed keywords

DISTEAROYLPHOSPHATIDYLETHANOLAMINE; ETOPOSIDE; MACROGOL; NANOMATERIAL; PHOSPHATIDYLETHANOLAMINE; POLYETHYLENEGLYCOL 40 STEARATE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CARCINOMA CELL; CONTROLLED STUDY; CYTOTOXICITY; DIFFUSION CHAMBER; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG TRANSPORT; EMULSION; HUMAN; HUMAN CELL; INTESTINE ABSORPTION; LOW TEMPERATURE; LUNG CARCINOMA; MALE; MAXIMUM PLASMA CONCENTRATION; NANOENCAPSULATION; NONHUMAN; PARTICLE SIZE; PHOTON CORRELATION SPECTROSCOPY; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; RAT; TIME TO MAXIMUM PLASMA CONCENTRATION; TRANSMISSION ELECTRON MICROSCOPY; ZETA POTENTIAL;

ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL AVAILABILITY; CELL LINE, TUMOR; DRUG CARRIERS; EMULSIONS; ETOPOSIDE; HUMANS; INTESTINES; LIPIDS; MALE; MUCOUS MEMBRANE; NANOPARTICLES; PARTICLE SIZE; PHOSPHATIDYLETHANOLAMINES; POLYETHYLENE GLYCOLS; RATS; RATS, SPRAGUE-DAWLEY; SEROUS MEMBRANE;

EID: 79956365448     PISSN: 09280987     EISSN: 18790720     Source Type: Journal    
DOI: 10.1016/j.ejps.2011.04.005     Document Type: Article

References (36)

1. Baldwin, E.L., Osheroff, N., 2005. Etoposide, topoisomerase II and cancer. Curr. Med. Chem. Anticancer Agents 5, 363-372.
2. Cavalli, R., Gasco, M.R., Chetoni, P., Burgalassi, S., Saettone, M.F., 2002. Solid lipid nanoparticles (SLN) as ocular delivery system for tobramycin. Int. J. Pharm. 238, 241-245.
3. Chattopadhyay, P., Shekunov, B.Y., Yim, D., Cipolla, D., Boyd, B., Farr, S., 2007. Production of solid lipid nanoparticle suspensions using supercritical fluid extraction of emulsions (SFEE) for pulmonary delivery using the AERx system. Adv. Drug Deliv. Rev. 59, 444-453.
4. Clark, P.I., Slevin, M.L., 1987. The clinical pharmacology of etoposide and teniposide. Clin. Pharmacokinet. 12, 223-252.
5. Dabholkar, R.D., Sawant, R.M., Mongayt, D.A., Devarajan, P.V., Torchilin, V.P., 2006. Polyethylene glycol-phosphatidylethanolamine conjugate (PEG-PE)-based mixed micelles: some properties, loading with paclitaxel, and modulation of P-glycoprotein-mediated efflux. Int. J. Pharm. 315, 148-157.
6. des Rieux, A., Fievez, V., Momtaz, M., Detrembleur, C., Alonso-Sande, M., Van Gelder, J., Cauvin, A., Schneider, Y.J., Preat, V., 2007. Helodermin-loaded nanoparticles: characterization and transport across an in vitro model of the follicle-associated epithelium. J. Control. Release 118, 294-302.
7. Desai, M.P., Labhasetwar, V., Amidon, G.L., Levy, R.J., 1996. Gastrointestinal uptake of biodegradable microparticles: effect of particle size. Pharm. Res. 13, 1838-1845.
8. Gao, Y., Gu, W., Chen, L., Xu, Z., Li, Y., 2008. The role of daidzein-loaded sterically stabilized solid lipid nanoparticles in therapy for cardio-cerebrovascular diseases. Biomaterials 29, 4129-4136.
9. García-Fuentes, M., Torres, D., Alonso, M.J., 2003. Design of lipid nanoparticles for the oral delivery of hydrophilic macromolecules. Colloids Surf. B Biointerfaces 27, 159-168.
10. Grass, G.M., Sweetana, S.A., 1988. In vitro measurement of gastrointestinal tissue permeability using a new diffusion cell. Pharm. Res. 5, 372-376.
11. Hattori, Y., Suzuki, S., Kawakami, S., Yamashita, F., Mitsuru Hashida, M., 2005. The role of dioleoylphosphatidylethanolamine (DOPE) in targeted gene delivery with mannosylated cationic liposomes via intravenous route. J. Control. Release 108, 484-495.
12. Hawley, A.E., Illum, L., Davis, S.S., 1997. Preparation of biodegradable, surface engineered PLGA nanospheres with enhanced lymphatic drainage and lymph node uptake. Pharm. Res. 14, 657-661.
13. Huang, G., Zhang, N., Bi, X., Dou, M., 2008. Solid lipid nanoparticles of temozolomide: potential reduction of cardial and nephric toxicity. Int. J. Pharm. 355, 314-320.
14. Hussain, N., Jaitley, V., Florence, A.T., 2001. Recent advances in the understanding of uptake of microparticulates across the gastrointestinal lymphatics. Adv. Drug Deliv. Rev. 50, 107-142.
15. Lim, S.J., Lee, M.K., Kim, C.K., 2004. Altered chemical and biological activities of alltrans retinoic acid incorporated in solid lipid nanoparticle powders. J. Control. Release 100, 53-61.
16. Liversidge, G.G., Cundy, K.C., 1995. Particle size reduction for improvement of oral bioavailability of hydrophobic drugs: I. Absolute oral bioavailability of nanocrystalline danazol in beagle dogs. Int. J. Pharm. 125, 91-97.
17. Luo, Y., Chen, D., Ren, L., Zhao, X., Qin, J., 2006. Solid lipid nanoparticles for enhancing vinpocetine's oral bioavailability. J. Control. Release 114, 53-59. (Pubitemid 44144503)
18. Kim, H., Davaa, E., Myung, C., Park, J., 2010. Enhanced siRNA delivery using cationic liposomes with new polyarginine-conjugated PEG-lipid. Int. J. Pharm. 392, 141-147.
19. Manjunath, K., Venkateswarlu, V., 2005. Pharmacokinetics, tissue distribution and bioavailability of clozapine solid lipid nanoparticles after intravenous and intraduodenal administration. J. Control. Release 107, 215-228. (Pubitemid 41319672)
20. Meresse, P., Dechaux, E., Monneret, C., Bertounesque, E., 2004. Etoposide: discovery and medicinal chemistry. Curr. Med. Chem. 11, 2443-2466.
21. Montecucco, A., Biamonti, G., 2007. Cellular response to etoposide treatment. Cancer Lett. 252, 9-18. (Pubitemid 46734551)
22. Muller, R.H., Radtke, M., Wissing, S.A., 2002. Nanostructured lipid matrices for improved microencapsulation of drugs. Int. J. Pharm. 242, 121-128.
23. Némati, F., Dubernet, C., Fessi, H., Colin de Verdière, A., Poupon, M.F., Puisieux, F., Couvreur, P., 1996. Reversion of multidrug resistance using nanoparticles in vitro: influence of the nature of the polymer. Int. J. Pharm. 138, 237-246.
24. Roger, E., Lagarce, F., Benoit, J.P., 2009. The gastrointestinal stability of lipid nanocapsules. Int. J. Pharm. 379, 260-265.
25. Ruckmani, K., Sivakumar, M., Ganeshkumar, P.A., 2006. Methotrexate loaded solid lipid nanoparticles (SLN) for effective treatment of carcinoma. J. Nanosci. Nanotechnol. 6, 2991-2995.
26. Sahu, A., Bora, U., Kasoju, N., Goswami, P., 2008. Synthesis of novel biodegradable and self-assembling methoxy poly(ethylene glycol)-palmitate nanocarrier for curcumin delivery to cancer cells. Acta Biomater. 4, 1752-1761.
27. Saitoh, H., Aungst, B.J., 1995. Possible involvement of multiple P-glycoprotein-mediated efflux systems in the transport of verapamil and other organic cations across rat intestine. Pharm. Res. 12, 1304-1310.
28. Serpe, L., Catalano, M.G., Cavalli, R., Ugazio, E., Bosco, O., Canaparo, R., Muntoni, E., Frairia, R., Gasco, M.R., Eandi, M., Zara, G.P., 2004. Cytotoxicity of anticancer drugs incorporated in solid lipid nanoparticles on HT-29 colorectal cancer cell line. Eur. J. Pharm. Biopharm. 58, 673-680.
29. Sezgin, Z., Yuksel, N., Baykara, T., 2007. Investigation of pluronic and PEG-PE micelles as carriers of meso-tetraphenyl porphine for oral administration. Int. J. Pharm. 332, 161-167.
30. Shah, J.C., Chen, J.R., Chow, D., 1989. Preformulation study of etoposide: identification of physicochemical characteristics responsible for the low and erratic oral bioavailability of etoposide. Pharm. Res. 6, 408-412.
31. Shono, Y., Nishihara, H., Matsuda, Y., Furukawa, S., Okada, N., Fujita, T., Yamamoto, A., 2004. Modulation of intestinal P-glycoprotein function by cremophor EL and other surfactants by an in vitro diffusion chamber method using the isolated rat intestinal membranes. J. Pharm. Sci. 93, 877-885.
32. Sivaramakrishnan, R., Nakamura, C., Mehnert, W., Korting, H.C., Kramer, K.D., Schafer-Korting, M., 2004. Glucocorticoid entrapment into lipid carriers - characterisation by paraelectric spectroscopy and influence on dermal uptake. J. Control. Release 97, 493-502. (Pubitemid 38802951)
33. Venkateswarlu, V., Manjunath, K., 2004. Preparation, characterization and in vitro release kinetics of clozapine solid lipid nanoparticles. J. Control. Release 95, 627-638. (Pubitemid 38344153)
34. Zhao, L., Feng, S., 2010. Enhanced oral bioavailability of paclitaxel formulated in vitamin E-TPGS emulsified nanoparticles of biodegradable polymers: in vitro and in vivo studies. J. Pharm. Sci. 99, 3552-3560.
35. Zhuang, C.Y., Li, N., Wang, M., Zhang, X.N., Pan, W.S., Peng, J.J., Pan, Y.S., Tang, X., 2010. Preparation and characterization of vinpocetine loaded nanostructured lipid carriers (NLC) for improved oral bioavailability. Int. J. Pharm. 394, 179-185.
36. Zur Muhlen, A., Schwarz, C., Mehnert, W., 1998. Solid lipid nanoparticles (SLN) for controlled drug delivery-drug release and release mechanism. Eur. J. Pharm. Biopharm. 45, 149-155.